

# ***In silico* Assessment of Galanthamine Alkaloids as Cytotoxic Agents and Brd4**

## **Inhibitors**

### **Abstract**

Cancer is associated with high mortality. The potential of Galanthamine alkaloids as cytotoxic agents and Brd4 inhibitors was investigated. Selected alkaloids were screened for cytotoxic properties using the Cell Line Cytotoxicity Predictor (CLCPred). The drug-likeness, physicochemical and pharmacokinetic properties of the compounds were determined using SwissADME. The interactions of the ligands with the Brd4 protein were investigated using SwissDock. Lastly, the toxicity of the compounds was investigated using SwissADME. The compounds showed cytotoxic potential against bone marrow neuroblastoma at  $Pa > 0.5$ . All the compounds satisfied Lipinski's, Verber's, and Muegge's conditions for drug-likeness. The binding energy of the alkaloids with Brd4 ranged between - 7.22 and - 7.82 kcalmol<sup>-1</sup>. Lycoramine with a binding energy of -7.82 kcalmol<sup>-1</sup> had comparable binding energy to those of the standard drug, doxorubicin (-7.91 kcalmol<sup>-1</sup>), and Brd4 inhibitors: Pelabresib (-7.96 kcalmol<sup>-1</sup>) and Birabresib (-8.43 kcalmol<sup>-1</sup>). The compounds were non-AMES toxic, non-carcinogens, and weak inhibitors of the human ether-a-go-go related gene (hERG). Galanthamine alkaloids showed potential for treating human bone marrow neuroblastoma. The results of this study have laid a foundation for subsequent in vitro and in vivo studies to establish the predicted activity.

**Keywords:** Cancer, Cytotoxicity, Brd4, alkaloids, SwissDock


## 1.0 INTRODUCTION

Cancer is a leading cause of death worldwide. Data from the World Cancer Research Fund International indicates that there are 18.1 million cancer cases worldwide in the year 2020 (WCRF, 2023); about 10 million persons died from the disease the same year (WHO, 2022). The global burden has been projected to rise to 27.5 million new cancer cases and 16.3 million cancer deaths by 2040 (ACS, 2023). The rapidly increasing incidence of cancer is due to various factors, including infections, genetic mutations, unhealthy diet, smoking, physical inactivity, and environmental pollutants (Budreviciute et al., 2020). The treatment options currently available for cancer include surgery, chemotherapy, radiation therapy, gene therapy, and hormonal therapy (Miller et al., 2022). Despite these therapeutic options, cancer mortality remains high. Furthermore, most of the chemotherapeutic agents currently in use have serious side effects (including hair loss, cardiac toxicity, gastrointestinal lesions, and neurologic dysfunction, among others) since they tend to attack normal cells alongside the cancerous cells (Zhong et al., 2021). These factors have necessitated the continuous search for new, cheaper, and less toxic anticancer agents. Herbs play a key role in treating diseases in traditional medicine. Phytochemicals are responsible for the biological activities displayed by plants (Kaushik et al., 2021) and are reported to be less toxic than their synthetic counterparts (Jha et al., 2022). Some phytochemicals of pharmacological importance used in cancer treatment include taxol, vincristine, vinblastine,

topotecan, irinotecan, and etoposide (Changxing et al., 2020). Up to 60% of drugs currently used in cancer treatment are natural products or their derivatives (Rayan et al., 2017).

Bromodomain-containing protein 4 (Brd4) is a key mediator of gene expression in cancers. For example, Brd4 expression is significantly up-regulated in NSCLC tissues and NSCLC cell lines with high invasion and metastasis potentials (Liao et al., 2016); Brd4 was highly over-expressed in primary and metastatic melanoma tissues and essential for melanoma tumor growth (Segura et al., 2013); Brd4 maintains c-Myc expression, thereby promoting aberrant self-renewal of AML cells (Zuber et al., 2011); Brd2 and Brd4 were significantly elevated in glioblastoma (Pastori et al., 2014); and Brd4 regulated breast cancer metastasis by modulating extracellular matrix gene expression (Alsarraj and Hunter, 2012). Results from several studies indicate that when the expression of Brd4 is inactivated or deregulated, cancer development is inhibited. For example, Brd4 inhibitor suppressed tamoxifen-resistant breast cancer cells growth (Feng et al., 2014); impaired cell invasion, accelerated cell apoptosis, and inhibited cell proliferation in NSCLC cell lines (Liao et al., 2016); demonstrated anti-leukemic effect in several human AML cell lines (Shi, J and Vakoc, 2014); and strongly attenuated melanoma cell proliferation in vitro and in vivo (Segura et al., 2013). Owing to the significant relationship between Brd4 expression and cancers, Brd4 is a promising therapeutic target in many malignancies (Filippakopoulos and Knapp, 2014; Jung et al., 2015). A significant amount of effort has been put into developing pharmacological inhibitors of Brd4 (some of these inhibitors have progressed to clinical and preclinical phases) (Liu et al., 2017; Zhang and Ma, 2018).

Galanthamine, an isoquinoline alkaloid, was first isolated from *Galanthus nivalis* and *Galanthus woronowii*, members of the Amaryllidaceae family (Heinrich, 2010). Galanthamine and its derivatives have since been isolated from several *Crinum* species (Refaat et al., 2012). Galanthamine was approved by the Food and Drug Administration (FDA) for treating mild to moderate stages of Alzheimer's Disease (Naguib et al., 2020). This investigation is an attempt at re-purposing this drug and its derivatives for possible use as anticancer agents. In this study, the potentials of Galanthamine-type alkaloids as cytotoxic agents and inhibitors of Brd4 were evaluated. The structures of the compounds investigated are presented in Figure 1.



Compound	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>
Galanthamine	βOH	Me	Me
Epinorgalanthamine	αOH	H	Me
Narwedine	O	Me	Me
Norgalanthamine	βOH	H	Me
Sanguinine	βOH	Me	H

**Fig.1:** Structures of Galanthamine Alkaloids under investigation

## 2.0 METHODOLOGY

## **2.1 Prediction of Cytotoxicity of Compounds**

The cytotoxic properties of the compounds were predicted using the online web service tool, Cell Line Cytotoxicity Predictor (<http://www.way2drug.com/cell-line/>). This tool uses the structural formula of compounds to predict their cytotoxic properties in normal and cancer cell lines. The cytotoxicity of the alkaloids (expressed as Pa and Pi values) was predicted by pasting their SMILE formats in the appropriate portal on the webtool server. Compounds with Pa > 0.5 are likely to possess good activity against a particular cell line; Pi expresses the probability that a compound would be inactive (Lagunin et al., 2018).

## **2.2 Prediction of Physicochemical and Pharmacokinetic Properties of Compounds**

The Physicochemical and Pharmacokinetic properties of the compounds were predicted by pasting their SMILE formats in the SwissADME online Web server (<https://www.swissadme.ch>). The drug-likeness of the compounds was assessed based on the cutoff points set by Lipinski, Veber and Muegge (Lipinski et al., 2001; Muegge et al., 2001; Veber et al., 2002).

## **2.3 Molecular Docking**

### **2.3.1 Ligand Preparation**

The alkaloids selected for investigation in the current study are Galanthamine (1), Epinorgalanthamine (2), Lycoramine (3), Narwedine (4), Norgalanthamine (5), and Sanguinine (6); while Birabresib (7), and Pelabresib (8), and Doxorubicin (9) were selected as standards against which the cytotoxicity and Brd4 inhibitory properties of the compounds were measured. Doxorubicin is a standard drug used in cancer treatment, while Birabresib (MK-8628/OTX015) and Pelabresib (CPI-0610) are selective inhibitors of Bromodomain and Extra-Terminal (BET) proteins (BRD2, BRD3, and BRD4) (Lewin et al., 2018; Blum et al., 2022). The structures of the

alkaloids and the standards were downloaded from the PubChem database in the SDF format. The structures were converted into the mol2 format before docking (O'Boyle et al., 2011).

### **2.3.2 Protein Preparation**

The Brd4 protein (PDB ID: 4JBX) was obtained from the protein databank. A Ramachandran plot of the protein was obtained using the PROCHECK server. The Ramachandran plot affirms the accuracy and reliability of the target protein, showing percentages of the protein backbone falling within the allowed and disallowed regions.

### **2.3.3 Molecular Docking**

The interaction of the ligands with the target protein was investigated using the SwissDock Server (<http://www.swissdock.ch/>) (Grosdidier et al., 2011), which sends a link containing the docking results for each compound to the user's email. The prediction (output file) gives information on the estimated binding energy, the full fitness score, and cluster rank, among others for each of the possible binding mode of the ligand. The lowest binding mode was selected as the one where the most favourable interaction exists between the protein and the ligand. After docking, Chimera was used to visualize and analyze the interactions between the protein and the ligands (Wafa and Mohamed, 2020).

### **2.3.4 Prediction of Toxicity of Alkaloids**

The toxicity of the compounds were assessed using ADMESAR (<http://lmmd.ecust.edu.cn/admetsar1/predict/>) by pasting their SMILE formats in the specified portal on the webpage (Daina et al., 2017).

## **3.0 RESULTS**

The potential cytotoxic properties of the compounds reported as Pa and Pi values are in Table 1. Pa indicates the probability that a compound would be active against a particular cell line while

Pi estimates the likelihood that the compound would be inactive. Table 1 shows that at  $P_a > 0.5$ , all the galanthamine alkaloids (except lycoramine (3)) demonstrated potential for cytotoxicity against the bone marrow neuroblastoma cell line (SH-SY5Y), with  $P_a$  values ranging between 0.588 and 0.657. The standard drug, Doxorubicin showed no likelihood for cytotoxicity at  $P_a > 0.5$ . The results also indicated that none of the alkaloids showed potential for activity against the normal cancer cell lines.

**Table 1: Prediction of Cytotoxicity of Compounds on Cancer Cell Lines (at  $P_a > 0.5$ )**

Ligands	Cancer Cell Line ( $P_a > 0.5$ )				Normal Cell Line ( $P > 0.5$ )
	$P_a$	$P_i$	Cell line	Cancer Cell Full name	
Galanthamine	0.623	0.003	SH-SY5Y	Bone marrow neuroblastoma	No activity
Epinorgalanthamine	0.657	0.003	SH-SY5Y	Bone marrow neuroblastoma	No activity
Lycoramine	No activity	No activity	No activity	-	No activity
Narwedine	0.588	0.003	SH-SY5Y	Bone marrow neuroblastoma	No activity
Norgalanthamine	0.657	0.003	SH-SY5Y	Bone marrow neuroblastoma	No activity
Sanguinine	0.624	0.003	SH-SY5Y	Bone marrow neuroblastoma	No activity
Doxorubicin	No activity	No activity	No activity	-	No activity

Table 2 shows that all the compounds satisfied Lipinski's, Verber's, and Muegge's rules for drug-likeness. The compounds had MlogP values ranging between 1.50 and 1.83.

**Table 2:** Physicochemical properties and drug likeness of the five inhibitors

Alkaloids	Physicochemical Properties						Drug likeness			
	MW	HBA	HBD	MR	TPSA (Å <sup>2</sup> )	NRB	MlogP	Lipinski	Veber	Muegge
1	287.35	4	1	84.05	41.93	1	1.74	Yes	Yes	Yes
2	273.33	4	2	79.15	50.72	1	1.50	Yes	Yes	Yes
3	289.37	4	1	84.52	41.93	1	1.83	Yes	Yes	Yes
4	285.34	4	1	83.09	38.77	1	1.66	Yes	Yes	Yes
5	273.33	4	1	79.15	50.72	1	1.50	Yes	Yes	Yes
6	273.33	4	2	79.58	52.93	0	1.50	Yes	Yes	Yes

MW- Molecular weight; HBA- Hydrogen Bond Acceptor; MR- Molar refractivity; TPSA-Total Polar Surface Area; NRB – No of Rotatable Bonds


The pharmacokinetic properties of the compounds are in Table 3. The compounds possess high gastrointestinal absorption, can penetrate the blood-brain barrier, and are substrates for Permeability glycoprotein (Pg-p).

**Table 3:** Pharmacokinetics properties of Investigated Compounds

Ligands	GI absorption	BBB permeant	P-gp substrate	CYP1A2 inhibitor	CYP2C19 inhibitor	CYP2C9 inhibitor	CYP3A4 inhibitor
1	High	Yes	Yes	No	No	No	No
2	High	Yes	Yes	No	No	No	No
3	High	Yes	Yes	No	No	No	No
4	High	Yes	Yes	No	No	No	Yes

5	High	Yes	Yes	No	No	No	No
6	High	Yes	Yes	No	No	No	No

The Ramachandran plot (Figure 2) shows that 94.5% of the target protein's residue (4JBX) falls within the preferred area (a protein model of excellent quality has 90% of its residue in the preferred areas).



**Fig. 2:** The Ramachandran plot

Table 4 shows the results obtained on docking the ligands with 4JBX. The binding energy of the alkaloids ranged between  $-7.22$  and  $-7.82$  kcalmol<sup>-1</sup>. Lycoramine with a binding energy of  $-7.82$  kcalmol<sup>-1</sup> had comparable binding energy to those of the standards, Pelabresib ( $-7.96$  kcalmol<sup>-1</sup>), Birabresib ( $-8.43$  kcalmol<sup>-1</sup>) and doxorubicin ( $-7.91$  kcalmol<sup>-1</sup>). Information on the

hydrogen bond interactions between the ligands and the protein residues is provided in Table 1, while Figure 3 shows the orientation of the compounds in the protein binding pockets.


**Table4** :Docking results of BET (4BJX) with selected Phytoconstituents

<b>Compound</b>	<b>Binding Affinity (kcal/mol)</b>	<b>Fullfitness</b>	<b>H-bonds</b>	<b>Length (A°)</b>
Galanthamine	-7.57	-608.3592	N...O ASN135	7.597
			N...O CYS136	6.926
			N...O MET132	8.646
Epinorgalanthamine	-7.31	-611.628	H12...O ASP88	5.865
Lycoramine	-7.82	-605.99664	N...O ASP88	7.009
Narwedine	-7.42	-600.20276	N...O CYS136	7.040
			N...O ASN135	7.760
			O1...HN GLN84	7.023
			O1...HN GLN85	7.393
Norgalanthamine	-7.22	-609.8246	H12...O ASP88	5.959
			O2...HN GLN84	8.223
Sanguinine	-7.40	-618.19995	N...O PHE79	8.345
Birabresib	-8.43	-310.7484	H21...O MET132	6.681
			H21...O MET105	7.674
			N3...O LYS91	6.987
			N2...O ASP88	7.235

---

			N2...O PRO82	7.596
			O...HN GLN85	7.274
			O...HN GLN84	6.826
			H14...O GLN85	5.640
			H14...O TRP81	5.371
			H14...O PRO86	5.560
Pelabresib	-7.96	-607.5853	H15...O GLY143	8.512
			N...HN MET149	7.843
			N...HN ALA150	8.225
Doxorubicin	-7.91	-572.25885	O10...HN	7.493
			LYS141	
			H19...O ASN93	7.161
			H19...O LEU92	4.974
			H16...O LEU92	4.174
			H19...O LYS91	6.219
			O9...HN ASP88	5.018
			H23...O LYS91	6.931
			H21...O PRO86	6.818
			O9,,,HN GLN85	6.424
			H21...O GLN85	7.349

---



**Fig. 3:** Docking poses of the compounds within the protein binding pockets

The results of the *in silico* toxicity screening of the compounds are in Table 5. The compounds are non-carcinogens, non-AMES toxic, and weak Inhibitors of Human Ether-a-go-related genes. In addition, they have high fish toxicity and are not readily biodegradable.

**Table 5:** Prediction of Toxicity of Compounds

Compound	Human Ether-a-go-go-Related Gene	AMES Toxicity	Carcinogens	Fish Toxicity	Biodegradation
Galanthamine	Weak inhibitor	Non AMES toxic	Non-carcinogens	High FHMT	Not ready biodegradable
Epinorgalanthamine	Weak inhibitor	Non AMES toxic	Non-carcinogens	High FHMT	Not ready biodegradable
Lycoramine	Weak inhibitor	Non AMES toxic	Non-carcinogens	High FHMT	Not ready biodegradable
Narwedine	Weak inhibitor	Non AMES toxic	Non-carcinogens	High FHMT	Not ready biodegradable
Norgalanthamine	Weak inhibitor	Non AMES toxic	Non-carcinogens	High FHMT	Not ready biodegradable
Sanguinine	Weak inhibitor	Non AMES toxic	Non-carcinogens	High FHMT	Not ready biodegradable

#### 4.0 DISCUSSIONS

Neuroblastoma accounts for about 8–10% of all childhood cancer cases (Smith et al., 2010). The disease affects 11 to 13 per million children under the age of 15; with the incidence varying from 1 per million in children aged between 10-14 years and 65 per million in children less than 1 year old (Hsieh et al., 2009; Kaatsch et al., 2006; Xie et al., 2018).

Based on various clinical parameters including age, stage, cellular differentiation/maturation, and biological markers at the time of diagnosis, children with Neuroblastoma are classified as low-risk, intermediate-risk, and high-risk (HR-NB). While the prognosis for the low-/intermediate-risk groups is favorable (with >90% overall survival), the HR-NB group has <50% five-year overall survival and poor long-term survival (Katta et al., 2023). It is imperative, therefore to develop more effective drugs that can arrest disease progression, and ensure the long-term survival of children with HR-NB. The results of this study show that Galanthamine-type alkaloids showed good potential as cytotoxic agents against bone marrow Neuroblastoma cancer cell lines. Furthermore, the galanthamine alkaloids investigated showed high selectivity towards the cancer cell line as they did not show any potential for activity against the normal cell lines at  $P_a > 0.5$ .

Lipinski's and Verber's rules measure the oral bioavailability of bioactive compounds while Muegge's rule measures the likelihood that a candidate would become a successful drug molecule from pharmacophore point calculation (Muegge, 2003). All the compounds studied satisfied Lipinski's, Verber's, and Muegge's conditions for drug-likeness, and are therefore potential lead agents for the treatment of Neuroblastoma. The topological polar surface area (TPSA) measures the fraction of the compound's surface area containing polar atoms. Compounds with a PSA less than  $140 \text{ \AA}^2$  exhibit better intestinal absorption (Mälkiä, 2004), while compounds with PSA values less than  $70 \text{ \AA}^2$  can penetrate the blood-brain barrier (Muchmore, 2010). All the compounds investigated had excellent intestinal absorption and can penetrate the blood-brain barrier (Table 3). However, the compounds are substrates for Permeability glycoprotein (P-gp). P-gp is an efflux transporter pump in the cell membrane that reduces the concentration of the drug by conveying it away from the cell membrane and cytoplasm, resulting in therapeutic failure. Therefore, for optimal performance, a drug candidate should possess excellent gastrointestinal

permeability and low P-gp liability (Geldenhuys et al., 2015). Though lycoramine showed no activity when it was screened for cytotoxicity *in silico* (at  $P_a > 0.5$ ), it had the least binding energy with the protein (4JBX) among the Galanthamine-type alkaloids studied, and had comparable binding energy with the standards: Doxorubicin, Birabresib, and Pelabresib.

Cancer has often been linked to mutations. The AMES test is used to assess the mutagenic potential of chemical compounds. In the current study, all the compounds gave a negative result on the test, implying that they are not potential carcinogens. The compounds are weak inhibitors of the human ether-a-go-go-related gene (hERG). hERG can be inhibited by marketed drugs, which may lead to QT prolongation and possibly fatal cardiac arrhythmia (Lamothe et al., 2016).

## **Conclusion**

The galanthamine-type alkaloids investigated demonstrated cytotoxic potential against human bone marrow neuroblastoma. All the compounds satisfied the conditions for drug-likeness. The binding energy of lycoramine with Brd4 is comparable to those of Doxorubicin, Birabresib, and Pelabresib. The compounds were non-AMES toxic, non-carcinogens, and weak inhibitors of hERG. Galanthamine alkaloids demonstrated potential for treating human bone marrow neuroblastoma. However, *in vitro* and *in vivo* studies need to be carried out to confirm the predicted activity.

## **REFERENCES**

Alsarraj J, Hunter KW (2012) Bromodomain-Containing Protein 4: A Dynamic Regulator of Breast Cancer Metastasis through Modulation of the Extracellular Matrix. *Int. J. Breast Cancer*. 2012:670632.

American Cancer Society (2023) Global Cancer Facts & Figures. (<https://amp.cancer.org/research/cancer-facts-statistics/global.html>) Access online: 09/07/23.

Blum KA, Supko JG, Maris MB, Flinn IW, Goy A, Younes A, Bobba S, Senderowicz AM, Efuni S, Rippley R et al. (2022) A phase I study of pelabresib (CPI-0610), a small-molecule inhibitor of BET proteins, in patients with relapsed or refractory lymphoma. *Cancer Res. Commun.* 2: 795–805.

Budreviciute A, Damiati S, Sabir DK, Onder K, Schuller-Goetzburg P, Plakys G, Katileviciute A, Khoja S, Kodzius R (2020) Management and Prevention Strategies for Non-communicable Diseases (NCDs) and Their Risk Factors. *Frontiers in Public Health* 8. <https://doi.org/10.3389/fpubh.2020.574111>

Changxing L, Galani S, Hassan F, Rashid Z, Naveed M, Fang D, Ashraf A, Qi W, Arif A, Saeed M, Arif Chishti AA, Jianhua L (2020) Biotechnological approaches to the production of plant-derived promising anticancer agents: An update and overview. *Biomedicine & Pharmacotherapy*. 132: 110918. <https://doi.org/10.1016/j.biopha.2020.110918>.

Daina A, Michielin O, Zoete V (2017) SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. *Scientific Reports*.7(1): 42717.

Feng Q, Zhang Z, Shea MJ, Creighton CJ, Coarfa C, Hilsenbeck SG, Lanz R, He B, Wang L, Fu X, Nardone A, Song Y, Bradner J, Mitsiades N, Mitsiades CS, Osborne CK, Schiff R, O'Malley BW (2014) An epigenomic approach to therapy for tamoxifen-resistant breast cancer. *Cell Res.* 24:809–819.

Filippakopoulos P, Knapp S (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. *Nat. Rev. Drug Discovery.* 13: 337–356.

Geldenhuis WJ, Mohammad AS, Adkins CE, Lockman PR (2015) Molecular determinants of blood–brain barrier permeation. *Ther Deliv* 6(8):961–971.

Grosdidier A, Zoete V, Michielin O (2011) SwissDock, a protein-small molecule docking web service based on EADock DSS. *Nucleic Acids Res.*39: 270-277.

Heinrich M (2010) Galanthamine from Galanthus and Other Amaryllidaceae – Chemistry and Biology Based on Traditional Use. *The Alkaloids: Chemistry and Biology*, 157–165. doi:10.1016/s1099-4831(10)06804-5

Hsieh MH, Meng MV, Walsh TJ, et al. (2009). Increasing incidence of neuroblastoma and potentially higher associated mortality of children from nonmetropolitan areas: Analysis of the surveillance, epidemiology, and end results database. *J Pediatr Hematol Oncol.*31: 942–46.

Jha V, Devkar S, Gharat K, Kasbe S, Matharoo DK, Pendse S, Bhosale A, Bhargava A (2022) Screening of Phytochemicals as Potential Inhibitors of Breast Cancer using Structure Based Multitargeted Molecular Docking Analysis. *Phytomedicine Plus.* 2(2): 100227. <https://doi.org/10.1016/j.phyplu.2022.100227>.

Jung M, Gelato KA, Fernandez-Montalvan A, Siegel S, Haendler B (2015) Targeting BET bromodomains for cancer treatment. *Epigenomics*. 7: 487–501.

Kaatsch P, Steliarova-Foucher E, Crocetti E, et al. (2006) Time trends of cancer incidence in European children (1978–1997): Report from the Automated Childhood Cancer Information System project. *Eur J Cancer*. 42:1961–71.

Kaushik B, Sharma J, Yadav K, Kumar P, Shourie A (2021). Phytochemical Properties and Pharmacological Role of Plants: Secondary Metabolites. *iosciBiotech Res. Asia*. 18(1).

Lagunin AA, Dubovskaja VI, Rudik AV, Pogodin PV, Druzhilovskiy DS, Glorizova TA, Filimonov DA, Sastry NG, Poroikov VV (2018) CLC-Pred: A freely available webservice for in silico prediction of human cell line cytotoxicity for drug-like compounds. *PLoS One* 25: 13(1):e0191838. doi: 10.1371/journal.pone.0191838.

Lewin J, Soria J, Stathis A, Delord J, Peters S, Awada A, Aftimos PG, Bekradda M, Rezaei K, Zeng Z, Hussain A, Perez S, Siu LL, Massard C. (2018) Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid Tumors. *Journal of Oncology*. 36(30): 3007-3014.

Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ, Ding JY (2016) High level of BRD4 promotes non-small cell lung cancer progression. *Oncotarget*. 7:9491–9500.

Liao YF, Wu YB, Long X, Zhu SQ, Jin C, Xu JJ, Ding JY (2016) High level of BRD4 promotes non-small cell lung cancer progression. *Oncotarget*. 23;7(8):9491-500. doi: 10.18632/oncotarget.7068.

Lipinski CA, Lombardo F, Dominy BW, Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. *Adv Drug Deliv Rev* 46: 3–26.

Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J (2017) Drug discovery targeting bromodomain-containing protein 4. *J MedChem* 60: 4533–4558.

Mälkiä A, Murtomäki L, Urtti A, Kontturi K (2004) Drug permeation in biomembranes: In vitro and in silico prediction and influence of physicochemical properties. *Eur J Pharm Sci* 23(1):13–47.

Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, Kramer J, Siegel RL (2022) Cancer treatment and survivorship statistics, 2022. *CA A Cancer J Clin*, 72: 409–436. <https://doi.org/10.3322/caac.21731>

Muchmore SW, Edmunds JJ, Stewart KD, Hajduk PJ (2010) Cheminformatic tools for medicinal chemists. *J Med Chem* 53(13):4830–4841.

Muegge I (2003) Selection criteria for drug-like compounds. *Medicinal Research Reviews*23(3): 302–321.

Muegge I, Heald SL, Brittelli D (2001) Simple selection criteria for drug-like chemical matter. *J. Med. Chem.* 44: 1841–1846.

Naguib S, Bernardo-Colón A, Cencer C, Gandra N, Rex TS (2020) Galantamine protects against synaptic, axonal, and vision deficits in experimental neurotrauma. *Neurobiology of Disease*. 134: 104695. <https://doi.org/10.1016/j.nbd.2019.104695>.

O'Boyle, NM, Banck M, James CA et al. (2011) Discovery and Development of Sorafenib: a multikinase inhibitor for treating cancer. *J. Cheminform.* 3:33. <https://doi.org/10.1186/1758-2946-3-33>

Pastori C, Daniel M, Penas C, Volmar CH, Johnstone AL, Brothers SP, Graham RM, Allen B, Sarkaria JN, Komotar RJ, Wahlestedt C, Ayad NG (2014) BET bromodomain proteins are required for glioblastoma cell proliferation. *Epigenetics.* 9: 611–620.

Rayan A, Raiyn J, Falah M (2017) Nature is the best source of anticancer drugs: indexing natural products for their anticancer bioactivity. *PLoS One* .12(11) doi: 10.1371/journal.pone.0187925.e0187925.

Refaat J, Kamel MS, Ramadan MA and Ali AA (2012) Crinum; An endless source of bioactive principles: A review. Part III; Crinum alkaloids: Belladine-, galanthamine-, lycorenine-, tazettine-type alkaloids and other minor types. *International Journal of Pharmaceutical Sciences and Research.* 3(10): 3630-3638.

Katta SS, Nagati V, Paturi ASV, Murakonda SP, Murakonda AB, Pandey MK, Gupta SC, Pasupulati AK, Challagundla KB (2023) Neuroblastoma: Emerging trends in pathogenesis, diagnosis, and therapeutic targets. *Journal of Controlled Release.* 357: 444-459, <https://doi.org/10.1016/j.jconrel.2023.04.001>.

Segura MF, Fontanals-Cirera B, Gazieli-Sovran A, Guijarro MV, Hanniford D, Zhang G, Gonzalez-Gomez P, Morante M, Jubierre L, Zhang W, Darvishian F, Ohlmeyer M, Osman I, Zhou MM, Hernando E (2013) BRD4 sustains melanoma proliferation and represents a new target for epigenetic therapy. *Cancer Res.* 73:6264–6276.

Lamothe SM, Guo J, Li W, Yang T, Zhang S (2016) The Human Ether-a-go-go-related Gene (hERG) Potassium Channel Represents an Unusual Target for Protease-mediated Damage. *Cell Biology*. 291(39): 20387-20401.

Shi J, Vakoc CR (2014) The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition. *Mol. Cell*. 54: 728.

Smith MA, Seibel NL, Altekrose SF, et al (2010) Outcomes for children and adolescents with cancer: Challenges for the twenty-first century. *J Clin Oncol*. 28:2625–34.

Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD (2002) Molecular Properties That Influence the Oral Bioavailability of Drug Candidates. *J. Med. Chem*. 45:2615–2623

Wafa T, Mohamed K (2020) Molecular Docking Study of COVID-19 Main Protease with Clinically Approved Drugs. *ChemRxiv*. doi.org/10.26434/chemrxiv.12318689.v1

World Cancer Research Fund International (2023) Worldwide Cancer Data. (<https://www.wcrf.org/cancer-trends/worldwide-cancer-data/>). Accessed online: 9/7/2023.

World Health Organization. Cancer (2022) <https://www.who.int/news-room/fact-sheets/detail/cancer#:~:text=Key%20facts,and%20rectum%20and%20prostate%20cancers>. Accessed online: 9/7/2023.

Xie L, Onysko J, Morrison H. (2018) Childhood cancer incidence in Canada: Demographic and geographic variation of temporal trends (1992–2010). *Health Promot Chronic Dis Prev Can*. 38:79–115.

Zhang F, Ma S (2018) Disrupting acetyl-lysine interactions: recent advance in the development of BET inhibitors. *Curr. Drug Targets*. 19: 1148–1165.

Zhong L, Li Y, Xiong L et al (2021) Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. *Sig Transduct Target Ther* 6: 201. <https://doi.org/10.1038/s41392-021-00572-w>

Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, Magoon D, Qi J, Blatt K, Wunderlich M, Taylor MJ, Johns C, Chicas A, Mulloy JC, Kogan SC, Brown P, Valent P, Bradner JE, Lowe SW, Vakoc CR (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. *Nature*. 478: 524–528.